White House docket posts temporary peptide access policy over FDA scientists' objections
The October 14 proposal would let licensed pharmacies compound and sell certain unapproved peptides, after an advisory panel with industry-linked members voted to loosen restrictions.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 20 13:16 ETSource: Physicians Weekly
The wire
- 01A temporary access policy appeared on a White House docket on Oct. 14 proposing to allow licensed pharmacies to make and sell certain unapproved peptides; FDA scientists had advised against it at a July meeting, citing inadequate clinical vetting.
- 02Compounders and telehealth operators would gain a pathway for peptides currently outside approval, a shift pushed by HHS Secretary Robert F. Kennedy Jr. and MAHA figures.
- 03KFF Health News reports many advisory panel members are new appointees with financial stakes in the peptide industry; HHS says all members meet FDA ethics requirements. The policy's final scope and peptide list are not yet set.
From the source
Read at physiciansweekly.comPeptide Supplement Facts & Fictions
Experimental peptides have become darlings among influencers, chiropractors, and doctors focused on longevity, antiaging, or “body optimization,” even though the FDA hasn’t approved them for safety or effectiveness. Health secretary Robert F. Kennedy Jr. and other leaders of the Make America Healthy Again movement have pushed to make unproven peptides more accessible — and they’ve gained traction.
